Drugs / ID93
Trials 9 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 16 trials | ||||||
| Phase 1 | NCT06714513 | May 2025 → Dec 2026 expected | pulmonary tuberculosis | Quratis Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT03806699 | Apr 2019 → Sep 2020 | tuberculosis | Quratis Inc. | Unknown | No outcome recorded |
| Phase 1 | NCT03722472 | Oct 2018 → Jun 2020 | pulmonary tuberculosis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 1 | NCT02508376 | Oct 2015 → Aug 2017 | tuberculosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT01927159 | Sep 2013 → Jul 2015 | pulmonary tuberculosis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 1 | NCT01599897 | Aug 2012 → May 2014 | pulmonary tuberculosis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT03806686 | May 2018 → Mar 2020 | tuberculosis | Quratis Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT02465216 | Jun 2015 → Jan 2017 | pulmonary tuberculosis | Access to Advanced Health Institute (AAHI) | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06670755 | Dec 2024 → Jul 2027 expected | tuberculosis | University of Oxford | Active not recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06205589 Comparator | Jul 2026 → Oct 2028 expected | pulmonary tuberculosis | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ID93 | “ID93 is a recombinant protein antigen comprising four antigens from Mycobacterium tuberculosis (Mtb).” NCT06714513 ↗ |
| Known as | ID93+GLA-SE | “Group 1/Phase 2a: ID93+GLA-SE 4 months and 6 months after start of TB treatment” NCT06205589 ↗ |
| Modality | Protein / enzyme biologic | “recombinant four-antigen Mycobacterium tuberculosis recombinant protein ID93” NCT01599897 ↗ |
| Route | Intramuscular | “administered intramuscularly alone or in combination” PMID 30210819 ↗ Sep 2018 |